SCHEMBL89783

SCHEMBL89783

COCCCOc1cc(N)c(F)cc1C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.34
KMT2A Q03164 4/20 0.34
HTT P42858 2/20 0.34
LMNA P02545 1/20 0.34
L3MBTL1 Q9Y468 3/20 0.33
TDP1 Q9NUW8 1/20 0.33
HTR2A P28223 2/20 0.33
RET P07949 1/20 0.32
KIF5B P33176 1/20 0.32
PRSS1 P07477 3/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.31
SLC6A4 P31645 1/20 0.31
TSHR P16473 1/20 0.31
TAAR1 Q96RJ0 1/20 0.31
ALDH1A1 P00352 4/20 0.31
MEN1 O00255 2/20 0.31
USP2 O75604 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL90173 0.84 LMNA (0.39) KDM4EKMT2AHTTLMNAL3MBTL1
SCHEMBL10440381 0.84 NCF1 (0.37) KDM4EKMT2AHTTL3MBTL1TDP1
SCHEMBL26633349 0.83 MAPT (0.46) KDM4EKMT2AHTTLMNAHTR2A
SCHEMBL3344836 0.81 ALOX5AP (0.38) KDM4EKMT2AHTTMRGPRX4SLC6A4
SCHEMBL2314552 0.81 L3MBTL1 (0.36) KDM4EKMT2AHTTLMNAL3MBTL1
SCHEMBL89538 0.81 TAAR1 (0.37) KDM4EKMT2AHTTL3MBTL1TDP1
SCHEMBL90718 0.80 POLB (0.37) KDM4EKMT2AL3MBTL1TDP1HTR2A
SCHEMBL1098907 0.76 TAAR1 (0.46) KDM4EKMT2AL3MBTL1TDP1TSHR
SCHEMBL89281 0.74 ALDH1A1 (0.44) KDM4EKMT2AHTTLMNAALDH1A1
SCHEMBL22138650 0.74 MRGPRX4 (0.47) KDM4ELMNAL3MBTL1TDP1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 KDM4E 1650/4885KMT2A 3129/4885HTT 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.